https://orcid.org/0000-0003-1724-4231
References
- Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016. Epub 2018/08/28. doi:10.1056/NEJMoa1805689.
- Hanna M, Ruberg FL, Maurer MS, et al. Cardiac scintigraphy with technetium-99m-Labeled Bone-Seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol. 2020;75(22):2851–2862. Epub 2020/06/06. doi:10.1016/j.jacc.2020.04.022.
- Muchtar E, Gertz MA, Kyle RA, et al. A modern primer on light chain amyloidosis in 592 patients with mass Spectrometry-Verified typing. Mayo Clin Proc. 2019;94(3):472–483. Epub 2019/02/17. doi:10.1016/j.mayocp.2018.08.006.
- Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404–2412. doi:10.1161/CIRCULATIONAHA.116.021612.
- Poterucha TJ, Elias P, Bokhari S, et al. Diagnosing transthyretin cardiac amyloidosis by technetium Tc 99m pyrophosphate. JACC Cardiovasc Imaging. 2021;14(6):1221–1231. doi:10.1016/j.jcmg.2020.08.027.